Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function

For patients with creatinine clearance between 50 and 95 ml/min, apixaban 5 mg was the most cost-effective treatment for willingness-to-pay thresholds (WTP) above $115,000/QALY gained, and edoxaban 60 mg was cost-effective when the WTP was between $75,000 and $115,000/QALY gained. For patients with creatinine clearance > 95 ml/min, apixaban 5 mg was the most cost-effective treatment for WTP thresholds above $80,000/QALY gained.